Cancel
Stephen Condon
Vice President, Chemistry
@
Venatorx Pharmaceuticals
s2h89u@sglufk5q.g17
Sign up to see email
See Linkedin
Known information
- Has been engaged in the discovery and development of bioactive compounds for over 25 years.
- Previously served in multiple roles at TetraLogic Pharmaceuticals.
- Led a team of scientists in the identification and evaluation of small molecule antagonists of the Inhibitor of Apoptosis (IAP) family of proteins.
- Worked with an international team of collaborators to uncover the central role of cellular IAP proteins in TNF signaling, inflammation, and tumor cell death.
- Contributed to the discovery of birinapant, a first-in-class bivalent IAP antagonist.
- Was Group Leader in Medicinal Chemistry at ViroPharma.
- Invented the first HCV NS5B inhibitor to demonstrate efficacy in the humanized mouse model of HCV infection.
- Began professional career at Rhône-Poulenc Rorer.
- His team at Rhône-Poulenc Rorer determined the bioactive conformation of human parathyroid [1-34] and developed anabolic peptides for the treatment of post-menopausal osteoporosis.
- Received a doctoral degree from the University of Pennsylvania.
- Completed dissertation with Professor Amos B. Smith III on the total synthesis of rapamycin and demethoxyrapamycin.
About Venatorx Pharmaceuticals
Venatorx Pharmaceuticals, founded in June 2010, focuses on developing novel anti-infectives to treat multi-drug-resistant bacterial and hard-to-treat viral infections. Their lead asset, cefepime-taniborbactam, has completed a Phase 3 study for complicated urinary tract infections and is under FDA review.
Report inaccurate information
